<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>New Tc-99m-labeled brain perfusion imaging agents, such as Tc-99m-HMPAO, and Tc-99m-<z:mp ids='MP_0010412'>ECD</z:mp>, are developed and expected to improve the clinical study of cerebral perfusion disturbance due to <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>They enable us better images than I-123-<z:chebi fb="54" ids="17202">IMP</z:chebi> and more accurate diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>Similarly, in the field of cardiovascular nuclear medicine, new Tc-99m-labeled compounds, Tc-99m-MIBI, Teboroxime and Tetrofosmin are available </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, I-123-MIBG, a tracer taken up in presynaptic adrenergic vesicles, and I-123-BMIPP, a new agent developed for the evaluation myocardial fatty acid metabolism, will mark a new epoch in the study of coronary <z:mp ids='MP_0000612'>sclerosis</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In order to image <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> directly, In-111-polyclonal immunoglobulin G, Tc-99m-<z:chebi fb="2" ids="39026">low density lipoprotein</z:chebi> etc., are under investigation </plain></SENT>
</text></document>